RecruitingNot ApplicableNCT03775837
Effect of Panax Ginseng C.A. Mey Extract on Liver Function in Adults
Effect of Panax Ginseng C.A. Mey Extract on Liver Function in Adults: a Randomized, Double-blinded, Placebo-controlled Trial
Sponsor
Pusan National University Yangsan Hospital
Enrollment
60 participants
Start Date
Dec 1, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Panax Ginseng C.A. Mey Extract on liver function in adults for 8 weeks.
Eligibility
Min Age: 19 YearsMax Age: 75 Years
Inclusion Criteria1
- ALT ranging from upper limit of reference to three times of upper limit
Exclusion Criteria8
- Abnormal liver or renal function (i.e., serum aminotransferase activity > 3 times of upper limit of reference range and serum creatinine concentrations > 1.2 mg/dL)
- Diabetes (diagnosed clinically or fasting glucose level > 126 mg/dL)
- History of viral hepatitis or cancer
- Uncontrolled hypertension
- History of serious cardiac disease such as angina or myocardial infarction
- History of gastrectomy
- History of medication for psychiatric disease
- Administration of oriental medicine including herbs within the past 4 weeks
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTPanax Ginseng C.A. Mey Extract group
This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
DIETARY_SUPPLEMENTPlacebo group
This group takes placebo for 8 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03775837
Related Trials
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
NCT060684918 locations
Development of a FibroScan Liver Examination Using a Single Probe
NCT074002894 locations
Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time
NCT068742969 locations
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
NCT062695101 location
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
NCT0682371314 locations